SynthesisNutrients2021
Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies.
Synthesis in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Examining the Association between Coffee Intake and the Risk of Developing Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.Nutrients · 2023Pooled it
- Non-pharmacological treatment of MASLD.Diabetologia · 2026Review
- Coffee as a polypharmacological modulator of mitochondrial health: from molecular mechanisms to translational implications.Journal of translational medicine · 2026Review
- Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- Gut microbiota supportive dietary pattern associated with reduced MASLD risk mediated by metabolomic profiles: a prospective cohort study.Nutrition journal · 2026Article
- Different types of sweetened coffee consumption, genetic predictor of gut microbe, and the risk of metabolic dysfunction-associated steatotic liver disease.Nutrition journal · 2026Article
- Association between coffee consumption habits and non-alcoholic fatty liver disease in community-dwelling populations: data from the National Health and Nutrition Examination Survey 2013-2018.Public health nutrition · 2026Article
- Review
- Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review.Nutrients · 2025Article
- Article
- Effect of coffee and coffee extract on liver function test in non-alcoholic fatty liver disease patients, a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2025Review
- Investigating the relationship between liver health status with coffee and tea consumption in participants referred to the Rafsanjan Cohort study in Iran.Scientific reports · 2024Article
- Review
- Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease.Foods (Basel, Switzerland) · 2024Review
- Complementary and alternative medicines and liver disease.Hepatology communications · 2024Review
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay.Life (Basel, Switzerland) · 2024Review
- Coffee, adenosine, and the liver.Purinergic signalling · 2024Review
- Beverage consumption in patients with metabolic syndrome and its association with non-alcoholic fatty liver disease: a cross-sectional study.Frontiers in nutrition · 2024Article
- Article
- Does caffeine have a double-edged sword role in inflammation and carcinogenesis in the colon?Intestinal research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimNon-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Given the anti-fibrotic and antioxidant properties of coffee, this systematic review and meta-analysis aims to provide updated results on the impact of coffee consumption on NAFLD incidence, prevalence, and risk of significant liver fibrosis.
methodsWe conducted a comprehensive search in MEDLINE (OvidSP) and Scopus from January 2010 through January 2021. Relative risks for the highest versus the lowest level of coffee consumption were pooled using random-effects models. Heterogeneity and publication bias were evaluated using the Higgins'
resultsEleven articles consisting of two case-control studies, eight cross-sectional studies, and one prospective cohort study were included in the meta-analysis. Of those, three studies with 92,075 subjects were included in the analysis for NAFLD incidence, eight studies with 9558 subjects for NAFLD prevalence, and five with 4303 subjects were used for the analysis of liver fibrosis. There was no association between coffee consumption and NAFLD incidence (RR 0.88, 95% CI 0.63-1.25,
conclusionThis meta-analysis supports the protective role of coffee consumption on significant liver fibrosis in patients with NAFLD. However, the threshold of coffee consumption to achieve hepatoprotective effects needs to be established in prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.